Gossamer Bio Inc. (GOSS) Announces $212M Private Placement Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Evercore ISI Downgrades Gossamer Bio Inc. (GOSS) to In Line, 'Long Path Ahead'
July 20, 2023 11:37 AM EDTEvercore ISI analyst Josh Schimmer downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Outperform to In Line with a price target of $4.00 (from $6.00).
The analyst comments "GOSS reported an initial look at the P2 OLE data for seralutinib in PAH, along with a large financing... More
